Image

Genomic Determinants of Outcome in Cardiogenic Shock

Genomic Determinants of Outcome in Cardiogenic Shock

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.

Description

This is a prospective observational cohort study in 8-10 cardiac centres across Europe. We will recruit patients presenting with acute myocardial infarction (AMI) and CS who are supported medically (n=100); with extracorporeal membrane oxygenation (n=50); and with the Impella Device (n=50). We will also enrol patients who present with either AMI and no evidence of CS (n=50) or CS due to non-ischaemic pathologies (e.g. myocarditis: n=50) as comparators. The recruitment target is 300 patients.

Eligibility

Inclusion Criteria:

  • All of the following are required for inclusion following screening:
    • Willing to provide informed consent or appropriate consent from a nominated consultee or personal consultee
    • Presentation within 24 hours of onset of ACS symptoms.
    • CS can only be secondary to ACS (Type 1 MI STEMI or N-STEMI) or myocarditis
    • Planned or completed revascularisation of culprit coronary artery

CS will be defined by:

  • Systolic blood pressure <90 mmHg for at least 30 minutes
  • A requirement for a continuous infusion of vasopressor or inotropic therapy to maintain systolic blood pressure > 90 mmHg.
  • Clinical signs of pulmonary congestion, plus signs of impaired organ perfusion with at least one of the following manifestations:
    • altered mental status.
    • cold and clammy skin and limbs.
    • oliguria with a urine output of less than 30 ml per hour.
    • elevated arterial lactate level of >2.0 mmol per litre.

Exclusion Criteria:

  • Any of the inclusion criteria not met and:
    1. Unwilling to provide informed consent.
    2. Echocardiographic evidence (recorded within 90 mins of end of PCI procedure) of mechanical cause for CS: eg ventricular septal defect, LV-free wall rupture, ischaemic mitral regurgitation.
    3. Age <18 and ≥80 years.
    4. Shock from another cause (sepsis, haemorrhagic/hypovolaemic shock, anaphylaxis, etc).
    5. Significant systemic illness
    6. Known dementia of any severity
    7. Comorbidity with life expectancy <12 months.
    8. Out-of-hospital cardiac arrest (OHCA) and any of the following:
      1. No return of spontaneous circulation (ongoing resuscitation effort)
      2. pH <7
      3. Without bystander CPR within 10 minutes of collapse
    9. Arterial lactate level of <2.0 mmol per litre.

Study details
    Cardiogenic Shock

NCT05728359

Barts & The London NHS Trust

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.